IL17A and Alzheimer disease: Additionally, tapinarof has been shown to reduce oxidative stress and modulate T cell function, specifically by decreasing IL13 and IL17a levels in tissue-resident T cells, which have been implicated in the pathogenesis of AD and psoriasis.